Managed Care Considerations in the Treatment and Management of Acute Myeloid Leukemia (AML): Optimizing Decision-Making Strategies for Improved Clinical and Economic Outcomes

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2022 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2023, to March 1, 2024

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
AbbVie and Jazz Pharmaceuticals

Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for roughly 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages. The American Cancer Society estimates that there were approximately 19,940 new cases of AML and 11,180 deaths from AML in the United States in 2021. The five-year survival rate has not improved in older patient’s despite of 40 years of research. Fortunately for patients with AML, many new treatments have recently been approved for use. These options, which are among the first new treatments in AML since 1990, have drastically changed the treatment paradigm. With that change comes a knowledge gap among physician medical directors, oncologists, practicing physicians and nurses. For this reason, it is critical that these HCPs are educated and updated on these emerging options and strategies for their implementation into the treatment paradigm which will ultimately improve patient outcomes in the AML patient population.

Upon completion of this activity, participants will be able to:

  • Examine the clinical and economic burden of AML in terms of relative survival, mortality, drug utilization, adverse event management, and hospitalizations

  • Compare and contrast the efficacy, safety and mechanisms of action of current therapeutics in AML, including newer targeted, cytotoxic, and antibody-based strategies, in a range of patient populations

  • Evaluate evolving secondary AML treatment strategies, including cytotoxic therapy options, and show patient- and tumor-specific features can inform decision-making in the context of outpatient care approaches

  • Discuss clinical and logistical challenges related to secondary AML and potential advantages of outpatient management for these patients

  • Assess the evolving role of BCL-2 inhibitors in patients with AML, including during maintenance

  • Review how patient- and tumor-specific features can inform clinical and managed care decision-making in secondary AML

  • Assess managed care considerations to facilitate optimal use of novel combination options, including cytotoxic therapy options, and optimal cost management in AML, including secondary AML


Faculty: Nicholas Short, MD
Assistant Professor
Department of Leukemia
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center


(Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Short has served as a consultant for Jazz Pharmaceuticals, Pfizer, and Sanofi. He has served on the speaker's bureau for Amgen, Astellas, Beigene, Novartis, and Sanofi. He has received grant/research support from Astellas, Stemline Therapeutics, Takeda Oncology, and Xencor. His presentation has been reviewed for any bias.
Planning Committee: Bill Williams, MD has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jeremy Williams has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
AbbVie and Jazz Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue